• The Nantes start-up BioMAdvanced Diagnostics announced this week a fundraising of 1.7 million euros.

  • She is working on an innovative diagnostic aid test to help doctors prevent rejection in lung and kidney transplant recipients.

This is a high-risk operation, which unfortunately results in half of the cases in rejection within five years.

But in the coming years, lung transplantation could be more tinged with success, hopes BioMAdvanced Diagnostics, which announced earlier this week a fundraising of 1.7 million euros.

This Nantes start-up with eight employees is working, in conjunction with the Nantes University Hospital in particular, on innovative diagnostic aid tests.

Objective of these calculations, based on an algorithm: to better predict the risks of rejection in the patient who has just been transplanted, of a lung therefore but also of a kidney.

“Thanks to a blood test, we can detect and quantify the RNA produced by specific rejection genes,” explains Frédéric Pette, co-founder and director of medtech.

A diagnosis so far very difficult for doctors to make, especially when we know that in a quarter of cases, for a kidney transplant, this reaction shows no clinical signs.

Because the new organ can be badly received by the patient's body, whose immune system sometimes turns against the graft, and destroys it.

This is why patients are given heavy treatments called “immunosuppressants”… which also have side effects, and in particular a risk of infection.

"The second cause of death after rejection", specifies Frédéric Pette.

“A wake-up call”

The test, which must be carried out every six to twelve months in the hospital as part of the transplant patient's regular examinations, should therefore make it possible to lighten his treatments if he is "green".

"If it is red, it is an alarm signal that will allow doctors to do other analyses, to take the rejection early enough to help the patient overcome it as well as possible", reports Frédéric Pette.

Two clinical performance studies will be conducted at the beginning of next year in parallel with a second fundraising, for a market launch expected in 2025.



“In 2021, more than 5,000 transplants took place in France, and the kidney transplant represents two thirds, advances BioMAdvanced Diagnostics.

The number of transplants increases every year and France has set itself the goal of performing between 6,760 and 8,530 transplants by 2026, i.e. 40% more than today.

The start-up hopes to distribute its solution in a dozen countries, and open a subsidiary in the United States.

Health

Hauts-de-France: Residents' organs saved 337 lives

Bordeaux

Bordeaux: Little Rémi, heart transplant patient, left the CHU after 14 months of care

  • Health

  • Nantes

  • Pays de la Loire

  • Graft

  • start-up